-
Product Insights
Chordoma - Drugs In Development, 2024
Empower your strategies with our Chordoma – Drugs In Development, 2024 report and make more profitable business decisions. Chordoma is a rare type of bone cancer that occurs in the bones of the spine or the base of the skull. It begins in cells that once made up structures in the developing embryo that then developed into the disks of the spine. Most of these cells are gone by the time of birth or soon after, but sometimes a few remain...
-
Product Insights
Meningioma - Drugs In Development, 2024
Empower your strategies with our Meningioma – Drugs In Development, 2024 report and make more profitable business decisions. A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid, and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of...
-
Product Insights
Primary CNS Lymphoma - Drugs In Development, 2024
Empower your strategies with our Primary CNS Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions. Primary CNS lymphoma (PCNSL) is a rare extranodal lymphoma that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement. It is a subtype on, and one of the most aggressive forms of, diffuse large B-cell lymphoma. PCNSL is more common in immunosuppressed patients, such as those with HIV/AIDS or transplant recipients, and is often associated with...
-
Product Insights
Hormone-Sensitive Prostate Cancer - Drugs In Development, 2024
Empower your strategies with our Hormone-Sensitive Prostate Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Hormone-sensitive prostate cancer (HSPC) is a type of prostate cancer that responds to hormone therapy, which aims to reduce or block the production or action of androgens such as testosterone. Androgens are male sex hormones that stimulate the growth of normal and cancerous prostate cells. Most prostate cancers are initially hormone-sensitive, but they may become castration-resistant over time, meaning that they...
-
Product Insights
Low-Grade Glioma - Drugs In Development, 2024
Empower your strategies with our Low-Grade Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Low-grade gliomas are benign grade 1 and grade 2 tumors of the brain or spinal cord, according to WHO classification. The development of these tumors may be brought on by environmental variables or genetic abnormalities. The tumor's size and location affect how it presents itself. Main causes include genetic mutations or environmental factors. Usually seizure is the first sign of a low-grade...
-
Product Insights
Pleomorphic Liposarcoma - Drugs In Development, 2024
Empower your strategies with our Pleomorphic Liposarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Pleomorphic liposarcoma is a rare and aggressive subtype of liposarcoma, a malignant tumor that arises from fat cells. Unlike other liposarcomas, pleomorphic liposarcoma is characterized by its pleomorphic, or varied and irregular, appearance under the microscope. This subtype often occurs in the deep soft tissues of the limbs and the retroperitoneum. Pleomorphic liposarcoma tends to be more challenging to treat than other...
-
Product Insights
B-Cell Chronic Lymphocytic Leukemia - Drugs In Development, 2024
Empower your strategies with our B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. B-cell chronic lymphocytic leukemia is a type of slow-growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms, or in the groin; pain or discomfort under the ribs on the left side due to an enlarged spleen; frequent or repeated infections and slow healing, due to a lack...
-
Product Insights
Ependymoma - Drugs In Development, 2024
Empower your strategies with our Ependymoma – Drugs In Development, 2024 report and make more profitable business decisions. Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow-growing tumours, and any signs and symptoms...
-
Product Insights
Hairy Cell Leukemia - Drugs In Development, 2024
Empower your strategies with our Hairy Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness, and weight loss. Risk factors include exposure to radiation, chemicals, and saw dust. Treatment includes surgery, chemotherapy, and radiation therapy. The Hairy Cell...
-
Product Insights
Testicular Cancer - Drugs In Development, 2024
Empower your strategies with our Testicular Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Testicular cancer stands out as a prevalent malignancy affecting men in the age group of 15 to 45 years. Its etiology is complex, involving a combination of genetic and environmental factors. Advancements in understanding the epidemiology, pathophysiology, and diagnostic approaches have paved the way for sophisticated management strategies. Notably, the prognosis for testicular cancer has significantly improved, boasting cure rates reaching up...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.